Cargando…

重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响

BACKGROUND AND OBJECTIVE: It is unclear how could endostatin effect tumor lymphangiogenesis? The aim of this study is to explore inhibitory effect of recombinant human endostatin injection (endostar) on lymphangiogenesis in non-small cell lung cancer (NSCLC) tissue and its effect on circulating tumo...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000404/
https://www.ncbi.nlm.nih.gov/pubmed/25342038
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.10.03
_version_ 1783331713303183360
collection PubMed
description BACKGROUND AND OBJECTIVE: It is unclear how could endostatin effect tumor lymphangiogenesis? The aim of this study is to explore inhibitory effect of recombinant human endostatin injection (endostar) on lymphangiogenesis in non-small cell lung cancer (NSCLC) tissue and its effect on circulating tumor cells (CTC) in peripheral blood. METHODS: Tumor-bearing model nude mice were divided into eight groups randomly (n=7), including control group, cisplatin group, several concentration endostar groups and endostar plus cisplatin groups. Continuous administration of Endostar for two weeks, observed one week after the end of administration. Using HE staining and immunohistochemical staining to diagnose the tumor tissue and suspect metastasis lymph nodes, detected vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGF receptor (VEGFR)-3 expression level and microlymphatic vessel density (MLVD) of tumor tissue. Enrichment of circulating tumor cells in peripheral blood used immunomagnetic negative selection strategy, used immunofluorescence staining to diagnose and count CTCs. RESULTS: Microlymphatic vessel density and the positive expression rate of VEGF-C, VEGF-D, VEGFR-3 in three endostar groups and three endostar plus cisplatin groups were significantly less than those in control group and cisplatin group. Microlymphatic vessel density and the positive expression rate of VEGF-C, VEGF-D, VEGFR-3 in endostar plus cisplatin group and endostar group with high endostar concentration were significantly less than those with low endostar concentration; There was a significant positive correlation between microlymphatic vessel density and the positive expression rate of VEGF-C, VEGF-D, VEGFR-3. The number of circulating tumor cells in endostar plus cisplatin groups were significantly less than that of endostar or cisplatin alone. CONCLUSION: Endostar could inhibit tumor lymphangiogenesis and reduce tumor cells into the bloodstream through the lymphatic. Inhibitory effect concerned with drug concentrationwith a dose-dependant.
format Online
Article
Text
id pubmed-6000404
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60004042018-07-06 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响 Zhongguo Fei Ai Za Zhi 基础研究 BACKGROUND AND OBJECTIVE: It is unclear how could endostatin effect tumor lymphangiogenesis? The aim of this study is to explore inhibitory effect of recombinant human endostatin injection (endostar) on lymphangiogenesis in non-small cell lung cancer (NSCLC) tissue and its effect on circulating tumor cells (CTC) in peripheral blood. METHODS: Tumor-bearing model nude mice were divided into eight groups randomly (n=7), including control group, cisplatin group, several concentration endostar groups and endostar plus cisplatin groups. Continuous administration of Endostar for two weeks, observed one week after the end of administration. Using HE staining and immunohistochemical staining to diagnose the tumor tissue and suspect metastasis lymph nodes, detected vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGF receptor (VEGFR)-3 expression level and microlymphatic vessel density (MLVD) of tumor tissue. Enrichment of circulating tumor cells in peripheral blood used immunomagnetic negative selection strategy, used immunofluorescence staining to diagnose and count CTCs. RESULTS: Microlymphatic vessel density and the positive expression rate of VEGF-C, VEGF-D, VEGFR-3 in three endostar groups and three endostar plus cisplatin groups were significantly less than those in control group and cisplatin group. Microlymphatic vessel density and the positive expression rate of VEGF-C, VEGF-D, VEGFR-3 in endostar plus cisplatin group and endostar group with high endostar concentration were significantly less than those with low endostar concentration; There was a significant positive correlation between microlymphatic vessel density and the positive expression rate of VEGF-C, VEGF-D, VEGFR-3. The number of circulating tumor cells in endostar plus cisplatin groups were significantly less than that of endostar or cisplatin alone. CONCLUSION: Endostar could inhibit tumor lymphangiogenesis and reduce tumor cells into the bloodstream through the lymphatic. Inhibitory effect concerned with drug concentrationwith a dose-dependant. 中国肺癌杂志编辑部 2014-10-20 /pmc/articles/PMC6000404/ /pubmed/25342038 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.10.03 Text en 版权所有©《中国肺癌杂志》编辑部2014 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 基础研究
重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响
title 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响
title_full 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响
title_fullStr 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响
title_full_unstemmed 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响
title_short 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响
title_sort 重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响
topic 基础研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000404/
https://www.ncbi.nlm.nih.gov/pubmed/25342038
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.10.03
work_keys_str_mv AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng
AT zhòngzǔrénxuèguǎnnèipíyìsùduìfēixiǎoxìbāofèiáilínbāguǎnshēngchéngdeyìzhìjíduìxúnhuánzhǒngliúxìbāodeyǐngxiǎng